Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00384046
Other study ID # 2005108
Secondary ID
Status Completed
Phase Phase 3
First received October 3, 2006
Last updated April 15, 2013
Start date November 2006
Est. completion date July 2007

Study information

Verified date April 2013
Source Warner Chilcott
Contact n/a
Is FDA regulated No
Health authority Canada: Health CanadaUnited States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to examine whether the transdermal testosterone system (TTS) is effective and safe in the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women who are on transdermal estrogen.


Description:

This is a randomised, double-blind, placebo-controlled, parallel-group, multicentre, 24 week study to be conducted in approximately 300 patients at approximately 14 clinical sites in the UK, 6 sites in Australia, 5 sites in Germany, and 2 sites in Canada. Women will be randomised 1:1 to receive 300 mcg/day TTS or placebo for a 24 week period. Consistent with previous phase III studies, efficacy will be assessed over 24 weeks using the Sexual Activity Log (SAL), and at 12 and 24 weeks using the Profile of Female Sexual Function (PFSF) and Personal Distress Scale (PDS). Safety will be assessed over the entire 24 weeks. Hormone data (free and total testosterone, total estradiol, and sex hormone binding globulin) will be collected at Weeks -4 and 24. The total duration of treatment for each patient is 24 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 272
Est. completion date July 2007
Est. primary completion date July 2007
Accepts healthy volunteers No
Gender Female
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria:

- Women will be screened for study participation according to the following inclusion criteria at Week -4. Eligible women must be a woman one year post menopausal, 40-70 years old in general good health on transdermal HRT and in a stable monogamous sexual relationship with low sexual desire causing distress.

Exclusion Criteria:

- Women will be screened for study participation according to the following exclusion criteria at Week -4 or as specified. Eligible women must not have any medical, physical, psychological, or pharmacological condition that could confound safety or efficacy.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Hypoactive Sexual Desire Disorder
  • Hypokinesia
  • Sexual Dysfunctions, Psychological

Intervention

Drug:
Testosterone
patch, 300 mcg/day testosterone, patch changed every 3-4 days, 24 weeks
Placebo
patch, placebo, patch changed every 3-4 days, 24 weeks

Locations

Country Name City State
Australia Research Facility Ashfield New South Wales
Australia Research Facility Dulwich South Australia
Australia Research Facility Gordon New South Wales
Australia Research Facility Nedlands Western Australia
Australia Research Facility Prahran Victoria
Australia Research Facility Randwick New South Wales
Botswana Research Facility Freiburg DEU
Canada Research Facility Montréal Quebec
Canada Research Facility Quebec City Quebec
Germany Research Facility Aachen
Germany Research Facility Hamburg
Germany Research Facility Münster
United Kingdom Research Facility Atherstone
United Kingdom Research Facility Coventry
United Kingdom Research Facility Doncaster
United Kingdom Research Facility Headington
United Kingdom Site Facility Headington Oxford
United Kingdom Research Facility Herts
United Kingdom Research Facility Leicester
United Kingdom Research Facility Leicester
United Kingdom Research Facility Lichfield
United Kingdom Research Facility London
United Kingdom Research Facility London
United Kingdom Research Facility London
United Kingdom Research Facility London
United Kingdom Research Facility London
United Kingdom Research Facility London
United Kingdom Research Facility Plymouth
United Kingdom Research Facility Salford
United Kingdom Research Facility Solihull West Midlands
United Kingdom Research Facility Warks

Sponsors (1)

Lead Sponsor Collaborator
Warner Chilcott

Countries where clinical trial is conducted

Australia,  Botswana,  Canada,  Germany,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary To assess the efficacy of the TTS by measuring change in frequency of total satisfying episodes. The safety assessment of TTS with various parameters. Assessment at 12 and 24 weeks No
Secondary To assess the efficacy of the TTS as measured by the following parameters: changes in sexual desire, personal distress, and other domains of PFSF and SAL questionnaires. Assessment at 12 and 24 weeks No
See also
  Status Clinical Trial Phase
Completed NCT02430987 - Low Sexual Desire and Metabolic Syndrome N/A
Completed NCT01432665 - Lybrido for Female Sexual Dysfunction Phase 2
Terminated NCT00551785 - Surveillance Study of Women Taking Intrinsa® Phase 4
Completed NCT03232801 - A Mindfulness-based Intervention for Older Women With Low Sexual Desire N/A
Recruiting NCT04179734 - Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder Phase 4
Terminated NCT02770768 - Effects of Flibanserin on the Pre- and Post-menopausal Female Brain N/A
Completed NCT01235754 - Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) Phase 3
Completed NCT03287232 - Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) Phase 3
Completed NCT00331123 - Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido Phase 3
Recruiting NCT04943068 - A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal) Phase 3
Completed NCT03463707 - BP101 for Adults With Female Sexual Dysfunction Phase 3
Completed NCT01208038 - Testosterone Patch's Effects on the Cardiovascular System and Libido Phase 4
Completed NCT00657501 - Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women Phase 3
Completed NCT04336891 - Effect of Testosterone Treatment on Clitoral Arteries' Hemodynamic Parameters.
Completed NCT01382719 - Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder Phase 2
Recruiting NCT00916396 - Dehydroepiandrosterone (DHEA) Treatment in Women and Men Experiencing Hypoactive Sexual Desire Disorder N/A
Completed NCT00034021 - Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction Phase 2
Completed NCT00338312 - Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido Phase 3
Completed NCT00331214 - Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido Phase 3
Recruiting NCT02968342 - Role of Progesterone in Hypoactive Sexual Desire Disorder in Menopausal Women Phase 4